<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306878</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-001</org_study_id>
    <nct_id>NCT00306878</nct_id>
  </id_info>
  <brief_title>Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris</brief_title>
  <official_title>Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to determine the safety, pharmacokinetics,
      immunogenicity in humans, the recovery time required from the biologic effects and the
      optimal biologic dose range of BMS188667 (CTLA4Ig)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date type="Actual">May 1997</completion_date>
  <primary_completion_date type="Actual">May 1997</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change relative to pretreatment of the Overall Disease Severity Score (ODSS) for psoriasis vulgaris as assess by a blinded observer. Phage-Neutralizing anitbody titer</measure>
    <time_frame>at Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's globas Assessment</measure>
    <time_frame>at Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phage-neutralizing antibody titer</measure>
    <time_frame>at Day 16 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage of anti-bacteriophage FX174 antibody of IgG isotype in sera collected</measure>
    <time_frame>at Day 43</time_frame>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women who received adequate counseling and were judged reliabel in their use of
             contraceptive measures.

          -  Diagnosis and documentation of stable psoriasis vulgaris of at least 6 months
             duration.

          -  Psoriasis vulgaris total body surface area involvement between 10% and 49% (Overall
             Disease Severity Score [ODSS]of 4-7 inclusive).

          -  Failure of toxicity or inefficacy of at least one standard antipsoriatic therapy
             including topical treatment, etretinate, phototherapy, or methotrexate.

        Exclusion Criteria:

          -  Treatment with: a) Retinoids within 2 years, b) cyclosporin A, systemic
             corticosteroids, methotrexate, or an investigational agent within 16 weeks, c) any
             phototherapy or photochemotherapy within 4 weeks d) any topical psoriasis treatment
             other than emollients within 2 weeks prior to enrollment.

          -  No clinical response to a prior adequate therapeutic trial of cyclosporin A

          -  Prolonged exposure to the sun within 4 weeks prior to the first dose.

          -  Guttate, erythrodermic, or pustular psoriasis.

          -  Spontaneously improving or rapidly deteriorating psoriasis vulgaris.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2006</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

